Which first-line treatment is superior in advanced colorectal cancer: XELOX or pviFOX?: Commentary

Nature Clinical Practice Oncology

Volumn 4, Issue 5, 2007, Pages 280-281

  Cassidy, James ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DEXAMETHASONE; FLUOROURACIL; GRANISETRON; OXALIPLATIN;

ADVANCED CANCER; BONE MARROW TOXICITY; CANCER GROWTH; CANCER REGRESSION; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG CHOICE; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; STOMATITIS; THROMBOCYTOPENIA;

EID: 34248541058     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0792     Document Type: Short Survey

References (3)

1. Tashiro T et al. (1989) Antitumour activity of a new platinum complex, oxalato (trans-1-1,2-diaminociclohexane) platinum (III), new experimental data. Biomed Pharmacother 43: 251-260
2. Cassidy J et al. (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 22: 2084-2091
3. Cassidy J et al. (2006) First efficacy and safety results from XELOX-1/NO16968, a randomized 2×2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC) [presidential symposium]. Ann Oncol 17 (Suppl 9) LBA3